« Previous
Next »
Digestive and Liver Disease
Volume 42, Issue 3
, Pages 173-174
, March 2010
Clinical relevance of the expression of somatostatin receptors in digestive endocrine tumours
References
- Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008;9:61–72
- Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. Endocr Relat Cancer. 2005;12:1083–1092
- Somatostatin receptor subtypes 2 and 5 are associated with better survival in well-differentiated endocrine carcinomas. Neuroendocrinology. 2009;89:223–230
- Somatostatin receptor subtype 5 (SSTR5) mRNA expression is related to histopathological features of cell proliferation in insulinomas. Endocr Relat Cancer. 2006;13:69–78
- Pancreatic endocrine tumors: expression profiling evidences a role for AKT–mTOR pathway. J Clin Oncol. 2009 November 16;[Epub ahead of print]
- Immunohistochemical expression of somatostatin receptors in digestive endocrine tumours. Dig Liver Dis. 2009 October 9;[Epub ahead of print] PubMed PMID: 19819769
- Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy. Mod Pathol. 2007;20:1172–1182
- Expression of somatostatin and dopamine 2 receptors in neuroendocrine tumours and the potential role for new biotherapies. Neuroendocrinology. 2009;89:308–314
- Somatostatin receptor tissue distribution in lung neuroendocrine tumours: a clinicopathologic and immunohistochemical study of 218 clinically aggressive cases. Ann Oncol. 2009 September 16;
PII: S1590-8658(10)00004-6
doi: 10.1016/j.dld.2009.12.009
© 2010 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Inc All rights reserved.
« Previous
Next »
Digestive and Liver Disease
Volume 42, Issue 3
, Pages 173-174
, March 2010
